Inverse agonists at A1 adenosine receptors in rat cerebral cortex

K. S. Park, W. S. Yang, K. H. Kim

Research output: Contribution to journalArticle

Abstract

According to the traditional receptor model, competitive antagonists share with agonists the ability to bind to a common site on receptors, but they are different from agonists in that they cannot trigger the biological response - i.e., they lack intrinsic efficacy. Recent findings extend the model by indicating that not all antagonists display an intrinsic efficacy of zero but that some display 'inverse agonism'. In the present study we studied the inverse agonism at A1 adenosine receptors in membranes prepared from rat cerebral cortex. Eight commercially available A1 adenosine receptor antagonists (CGS-15943, ADPX, CPT, DPCPX, DPX, N-0840, PACPX and 8-PT) were screened for inverse agonism by measuring the extent of [35S]guanosine-5'-(γ-thio) triphosphate ([35S]GTPγS) binding to G proteins. The agonist-induced stimulation of [35S]GTPγS bindings was completely blocked in the presence of A1 adenosine receptor antagonists. Under optimal conditions, two types of antagonists could be distinguished. Seven antagonists including DPCPX decreased the basal [35S]GTPγS binding in the absence of agonist, displaying inverse agonist activity. One (CGS-15943) had no effect on the basal bindings. N-ethylmaleimide treatment reduced the basal bindings as well as agonist-mediated stimulation of [355S]GTPγS bindings, indicating that a substantial amount of this binding reflects an activated state of the G proteins. In good agreement with these findings, 0.1 mM GTP decreased the apparent affinity of the receptors for the agonist PIA, increased that for DPCPX, and had no effect on that for CGS-15943.

Original languageEnglish
Pages (from-to)23-29
Number of pages7
JournalKorean Journal of Pharmacology
Volume32
Issue number1
Publication statusPublished - 1996 Jan 1

Fingerprint

Adenosine A1 Receptor Agonists
Adenosine A1 Receptor Antagonists
Cerebral Cortex
GTP-Binding Proteins
Adenosine A1 Receptors
Ethylmaleimide
Guanosine
Guanosine Triphosphate
Membranes
1,3-dipropyl-8-cyclopentylxanthine
9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Park, K. S. ; Yang, W. S. ; Kim, K. H. / Inverse agonists at A1 adenosine receptors in rat cerebral cortex. In: Korean Journal of Pharmacology. 1996 ; Vol. 32, No. 1. pp. 23-29.
@article{870ee14f14344bc78c963c9b985451df,
title = "Inverse agonists at A1 adenosine receptors in rat cerebral cortex",
abstract = "According to the traditional receptor model, competitive antagonists share with agonists the ability to bind to a common site on receptors, but they are different from agonists in that they cannot trigger the biological response - i.e., they lack intrinsic efficacy. Recent findings extend the model by indicating that not all antagonists display an intrinsic efficacy of zero but that some display 'inverse agonism'. In the present study we studied the inverse agonism at A1 adenosine receptors in membranes prepared from rat cerebral cortex. Eight commercially available A1 adenosine receptor antagonists (CGS-15943, ADPX, CPT, DPCPX, DPX, N-0840, PACPX and 8-PT) were screened for inverse agonism by measuring the extent of [35S]guanosine-5'-(γ-thio) triphosphate ([35S]GTPγS) binding to G proteins. The agonist-induced stimulation of [35S]GTPγS bindings was completely blocked in the presence of A1 adenosine receptor antagonists. Under optimal conditions, two types of antagonists could be distinguished. Seven antagonists including DPCPX decreased the basal [35S]GTPγS binding in the absence of agonist, displaying inverse agonist activity. One (CGS-15943) had no effect on the basal bindings. N-ethylmaleimide treatment reduced the basal bindings as well as agonist-mediated stimulation of [355S]GTPγS bindings, indicating that a substantial amount of this binding reflects an activated state of the G proteins. In good agreement with these findings, 0.1 mM GTP decreased the apparent affinity of the receptors for the agonist PIA, increased that for DPCPX, and had no effect on that for CGS-15943.",
author = "Park, {K. S.} and Yang, {W. S.} and Kim, {K. H.}",
year = "1996",
month = "1",
day = "1",
language = "English",
volume = "32",
pages = "23--29",
journal = "Korean Journal of Physiology and Pharmacology",
issn = "1226-4512",
publisher = "Korean Physiological Soc. and Korean Soc. of Pharmacology",
number = "1",

}

Inverse agonists at A1 adenosine receptors in rat cerebral cortex. / Park, K. S.; Yang, W. S.; Kim, K. H.

In: Korean Journal of Pharmacology, Vol. 32, No. 1, 01.01.1996, p. 23-29.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inverse agonists at A1 adenosine receptors in rat cerebral cortex

AU - Park, K. S.

AU - Yang, W. S.

AU - Kim, K. H.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - According to the traditional receptor model, competitive antagonists share with agonists the ability to bind to a common site on receptors, but they are different from agonists in that they cannot trigger the biological response - i.e., they lack intrinsic efficacy. Recent findings extend the model by indicating that not all antagonists display an intrinsic efficacy of zero but that some display 'inverse agonism'. In the present study we studied the inverse agonism at A1 adenosine receptors in membranes prepared from rat cerebral cortex. Eight commercially available A1 adenosine receptor antagonists (CGS-15943, ADPX, CPT, DPCPX, DPX, N-0840, PACPX and 8-PT) were screened for inverse agonism by measuring the extent of [35S]guanosine-5'-(γ-thio) triphosphate ([35S]GTPγS) binding to G proteins. The agonist-induced stimulation of [35S]GTPγS bindings was completely blocked in the presence of A1 adenosine receptor antagonists. Under optimal conditions, two types of antagonists could be distinguished. Seven antagonists including DPCPX decreased the basal [35S]GTPγS binding in the absence of agonist, displaying inverse agonist activity. One (CGS-15943) had no effect on the basal bindings. N-ethylmaleimide treatment reduced the basal bindings as well as agonist-mediated stimulation of [355S]GTPγS bindings, indicating that a substantial amount of this binding reflects an activated state of the G proteins. In good agreement with these findings, 0.1 mM GTP decreased the apparent affinity of the receptors for the agonist PIA, increased that for DPCPX, and had no effect on that for CGS-15943.

AB - According to the traditional receptor model, competitive antagonists share with agonists the ability to bind to a common site on receptors, but they are different from agonists in that they cannot trigger the biological response - i.e., they lack intrinsic efficacy. Recent findings extend the model by indicating that not all antagonists display an intrinsic efficacy of zero but that some display 'inverse agonism'. In the present study we studied the inverse agonism at A1 adenosine receptors in membranes prepared from rat cerebral cortex. Eight commercially available A1 adenosine receptor antagonists (CGS-15943, ADPX, CPT, DPCPX, DPX, N-0840, PACPX and 8-PT) were screened for inverse agonism by measuring the extent of [35S]guanosine-5'-(γ-thio) triphosphate ([35S]GTPγS) binding to G proteins. The agonist-induced stimulation of [35S]GTPγS bindings was completely blocked in the presence of A1 adenosine receptor antagonists. Under optimal conditions, two types of antagonists could be distinguished. Seven antagonists including DPCPX decreased the basal [35S]GTPγS binding in the absence of agonist, displaying inverse agonist activity. One (CGS-15943) had no effect on the basal bindings. N-ethylmaleimide treatment reduced the basal bindings as well as agonist-mediated stimulation of [355S]GTPγS bindings, indicating that a substantial amount of this binding reflects an activated state of the G proteins. In good agreement with these findings, 0.1 mM GTP decreased the apparent affinity of the receptors for the agonist PIA, increased that for DPCPX, and had no effect on that for CGS-15943.

UR - http://www.scopus.com/inward/record.url?scp=0029822913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029822913&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029822913

VL - 32

SP - 23

EP - 29

JO - Korean Journal of Physiology and Pharmacology

JF - Korean Journal of Physiology and Pharmacology

SN - 1226-4512

IS - 1

ER -